Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.

Background: Antimuscarinics have shown modest efficacy with unwanted side effects in patients with overactive bladder (OAB). Efficacy of vibegron, a new β3-adrenergic receptor agonist, for OAB is unknown.

Objective: To evaluate the efficacy of once-daily oral vibegron in OAB patients (primary), and its safety, tolerability, and efficacy when administered alone or concomitantly with tolterodine (secondary).

Authorship issues at a New Zealand academic institution.

Background: Authorship of peer-reviewed publications can create conflict among academics.

Objective: To document authorship conflicts of academics at a tertiary faculty.

Methods: An anonymous questionnaire eliciting authorship conflicts and knowledge of authorship criteria was administered online to 154 academic staff members at a New Zealand university.

Efficacy of Solifenacin on Overactive Bladder Symptoms, Symptom Bother, and Other Patient-Reported Outcomes in Subjects With or Without Incontinence: A Post Hoc Analysis of Data From VIBRANT.

Objective: : To evaluate the efficacy of solifenacin versus placebo by baseline continence status using post hoc analysis.

Methods: : Patients with overactive bladder (OAB) were randomized to solifenacin or placebo for 12 weeks; patient-reported outcome (PRO) measures and bladder diaries were completed at prespecified time points. VESIcare Investigation of Bother and Quality of Life in Subjects with OAB (VIBRANT) was not designed to show treatment differences within continence status subgroups.

Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial.

Aim: The aim of this study was to evaluate the efficacy of solifenacin on symptom bother using the Overactive Bladder Questionnaire (OAB-q).

Methods: In VIBRANT, a double-blind, US-based trial, patients with OAB for > or = 3 months received flexibly dosed solifenacin or placebo for 12 weeks. At baseline and 4-week intervals, patients completed the OAB-q [symptom bother and health-related quality of life (HRQL) scales] and 3-day bladder diaries; other patient-reported outcome measures were also assessed at baseline and week 12.

Ureteral duplication with lower pole ectopia to the vas: a case report of an exception to the Weigert-Meyer law.

We report an unusual case of ureteral duplication with lower-pole ectopia and ureterolithiasis, which violates the Weigert-Meyer law. The duplicated ureter arose from a lower-pole calyx and drained inferiorly into the ipsilateral vas. A presentation of the case is followed by a comparison to the only known similar one, reported in 1988.